Drug pricing matters, but pipelines matter even more.
4don MSNOpinion
Is Pfizer on track to launch its next Lipitor -- this time in the weight-loss market?
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes ...
By Jonathan Stempel June 24 (Reuters) - Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing prices ...
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging ...
Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S. District Court for the District of Delaware. Vyndamax remains the market leader ...
Pfizer announced yesterday it was settling an epic legal battle with the Indian drugmaker Ranbaxy Laboratories that will keep generic versions of the best-selling cholesterol medicine Lipitor off the ...
(Reuters) - U.S. regulators granted Pfizer Inc a reissued patent on its multibillion-dollar Celebrex pain drug that extends its marketing exclusivity until early December 2015, the company said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results